<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04930874</url>
  </required_header>
  <id_info>
    <org_study_id>CA-COVID 196/10-6-2021</org_study_id>
    <nct_id>NCT04930874</nct_id>
  </id_info>
  <brief_title>Cerebral Autoregulation and COVID-19</brief_title>
  <acronym>CA-COVID</acronym>
  <official_title>Cerebral Autoregulation and Severe Coronavirus Disease 19 [CA-COVID]: A Single-center Physiological Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Athens</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess cerebral autoregulation by near-infrared spectroscopy (NIRS) in&#xD;
      patients with severe coronavirus disease 19 (COVID-19). Results on COVID-19 participants will&#xD;
      be compared with prior results of patients with septic shock and cardiac arrest, who&#xD;
      participated in NCT03649633 and NCT02790788, respectively.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background and Rationale:&#xD;
&#xD;
      Septic encephalopathy is a serious complication of sepsis / septic shock. In postmortem,&#xD;
      human brain samples, two forms of neuraxonal injury have been described, namely, scattered&#xD;
      ischemic lesions and diffuse injury. Prior evidence suggests that cerebral autoregulation is&#xD;
      impaired in patients with septic shock, and this may render the central nervous system more&#xD;
      vulnerable to direct ischemic damage, especially during episodes of hypotension. Recent&#xD;
      observational data suggest that impaired cerebral autoregulation is associated with death&#xD;
      within 3 months in patients with septic shock. Near-infrared spectroscopy (NIRS) constitutes&#xD;
      an established method of noninvasive assessment of cerebral autoregulation and also provides&#xD;
      the capability of semiquantitative assessment of regional cerebral blood flow. Severe&#xD;
      coronavirus disease (COVID-19) is characterized by hypoxemia due to pneumonia, thromboembolic&#xD;
      events that often affect the cerebral and pulmonary vascular network, vasodilatory shock and&#xD;
      multiorgan failure. Pathophysiological mechanisms have features in common with those of&#xD;
      septic shock and include &quot;cytokine storm&quot;, diffuse vascular endothelial involvement, micro-&#xD;
      and macro-vascular thrombosis and dysregulation of micro-circulation and vascular tone. In&#xD;
      the present study, the following 3 hypotheses will be tested: 1. Cerebral autoregulation is&#xD;
      likely to be severely impaired or even abolished in patients with COVID-19 who require&#xD;
      admission to an Intensive Care Unit (ICU). In addition, the correlation between the NIRS&#xD;
      Tissue Oxygenation Index and the mean arterial pressure may be stronger in COVID-19 compared&#xD;
      to septic shock and comparable to that determined after cardiac arrest. 2. Cerebral&#xD;
      autoregulation is likely to be associated with known COVID-19 severity markers such as&#xD;
      lymphopenia and elevated C-reactive protein (CRP), ferritin, delta dimers (D-dimers) and&#xD;
      lactate dehydrogenase (LDH) 3. The early (ie on ICU days 1 and 3) absence of cerebral&#xD;
      autoregulation is likely to be associated with residual neurological deficits.&#xD;
&#xD;
      METHODS:&#xD;
&#xD;
      NIRS monitoring will be performed for approximately 90 minutes at 2 mean blood pressure&#xD;
      levels (MAP, i.e. 65-70 mmHg and 95-100 mmHg) within 12-48 hours and 60-84 hours after&#xD;
      admission to the ICU for severe COVID-19 infection. Autoregulation will be assessed using&#xD;
      Tissue Oxygenation Index values and mean arterial pressure (MAP) values in a regression&#xD;
      analysis and will be considered sufficient if the relative Pearson correlation coefficient is&#xD;
      less than 0.3 Cerebral blood flow will be assessed by blood flow index (BFI) determination&#xD;
      after intravenous infusion of 5 mg indocyanine.&#xD;
&#xD;
      ICU Protocol: All COVID-19 patients participating in this study will be treated in a&#xD;
      standardized manner that includes: An intermediate dose of Enoxaparin, e.g. 4000 units x 2&#xD;
      subcutaneously 2. Treatment with remdesivir and dexamethasone 3. Up to 2 broad-spectrum&#xD;
      antibiotics to treat possibly co-existing bacterial respiratory tract infection 4. A&#xD;
      conservative fluid management strategy 5. A protective ventilation strategy in a&#xD;
      semirecumbent position 5. Anesthesia with Midazolam, Propofol and Remifentanil 7. Enteral&#xD;
      nutrition that will start within 24 hours after admission to the ICU, 8. Permissive&#xD;
      hyperglycemia (blood glucose 150-200 mg / dL).&#xD;
&#xD;
      Data Collection and Patient Monitoring:&#xD;
&#xD;
      Monitoring of patients during the first 10 days after inclusion in the study will include 1)&#xD;
      Determination and recording of hemodynamic parameters and hemodynamic support, blood gases&#xD;
      and arterial blood lactate at 9 p.m. 2) Blood sampling at 24-48, 72 hours and 7 days after&#xD;
      inclusion in the study for determination of serum cytokines and 3) Daily recording of&#xD;
      laboratory values, fluid balance and administration. The results of 2-4 daily determinations&#xD;
      of blood glucose will be recorded and then the incidence of hyperglycemia (defined as blood&#xD;
      glucose in excess of 200 mg) will be analyzed. Follow-up until day 60 after inclusion in the&#xD;
      study will include organic failures and the number of days without mechanical ventilatory&#xD;
      assistance. Finally, the length of stay in the ICU, the date of discharge from the hospital&#xD;
      and the morbidity and complications throughout the patient's treatment until discharge from&#xD;
      the hospital will be recorded.&#xD;
&#xD;
      Predefined comparisons: The severity of cerebral autoregulation disturbance in patients with&#xD;
      COVID-19 will be compared with the cerebral autoregulation disturbance in 1) patients with&#xD;
      septic shock (n = 32, NCT03649633, www.clinicaltrials.gov) and 2) cardiac arrest (n = 30,&#xD;
      NCT02790788, www.clinicaltrials.gov). Also, other -pre-specified -by the respective research&#xD;
      protocols- patient monitoring variables will be compared between the aforementioned groups of&#xD;
      patients.&#xD;
&#xD;
      Names / degrees of Associates:&#xD;
&#xD;
      Alexandros Kouvarakos, Physiotherapist; Eirini Patsaki, Physiotherapist; Sotirios Malachias,&#xD;
      MD, PhD; Charikleia Vrettou, MD, PhD; Stylianos Kokkoris, MD, PhD; Prodromos Temperikidis,&#xD;
      MD, PhD; Aggeliki Kannavou, MD, PhD; George Adamos, MD, PhD&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2021</start_date>
  <completion_date type="Anticipated">February 16, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 16, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cerebral autoregulation</measure>
    <time_frame>Days 1-4 of ICU admission</time_frame>
    <description>The tissue oxygenation index of the frontal cortex will be determined (at a rate of 180 measurements / min) while increasing MAP from a minimum of 65-75 mmHg to a maximum of 90-100 mmHg by changing the vasopressor infusion rate. Cooncurrent changes in MAP will also be recorded. Subsequently, linear regression between MAP and the Tissue Oxygenation Index will be performed. A Pearson correlation coefficient of &gt;0.3 will be considered as &quot;absence&quot; of autoregulation of the cerebral vasculature.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cerebral blood flow</measure>
    <time_frame>Days 1-4 of ICU admission</time_frame>
    <description>Cerebral blood flow at MAP 65-75 mmHg and MAP 90-100 mmHg by determination of the blood flow index.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurologic failure free days</measure>
    <time_frame>Days 1-60 after ICU admission</time_frame>
    <description>Days without neurologic failure throughout the 60-day follow-up period. Patients with a Glasgow Coma Scale of &lt;9 will be considered to have neurological failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator free days</measure>
    <time_frame>Days 1-60 after ICU admission</time_frame>
    <description>Days without mechanical ventilatory assistance throughout the 60-day follow-up period. On any given day of follow-up, patients will be considered as &quot;ventilator-free&quot; only if there is no need for respiratory support within the preceding 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival to hospital discharge and neurological outcome</measure>
    <time_frame>Days 1-60 after ICU admission</time_frame>
    <description>Survival to hospital discharge and neurological outcome assessed by the Cerebral Performance Category Score, and the Modified Rankin Scale Score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival to hospital discharge and neurological outcome</measure>
    <time_frame>Days 1-60 after ICU admission</time_frame>
    <description>Survival to hospital discharge and neurological outcome assessed by the Cerebral Performance Category (CPC) Score. The CPC Score ranges from 1 to 5, with 1 corresponding to the best possible outcome (i.e. patient able to work and lead a normal life), and 5 corresponding to the worst possible outcome (i.e. brain death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival to hospital discharge and neurological outcome</measure>
    <time_frame>Days 1-60 after ICU admission</time_frame>
    <description>Survival to hospital discharge and neurological outcome assessed by the Modified Rankin Scale (mRS) Score. The mRS ranges from 0, corresponding to the best possible outcome (i.e. no symptoms related to a neurological deficit), to 6 corresponding to the worst possible outcome (i.e. death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Cytokines</measure>
    <time_frame>Days 1-7 after ICU admission</time_frame>
    <description>Tumor Necrosis Factor alpha, Interleukin (IL)-1 beta, IL-6, IL-8, and IL-10 levels at 24-48, 72 hours and 7 days after enrollment. Plasma concentrations of all the aforementioned cytokines will be expressed in picograms per milliliter.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>COVID-19 Acute Respiratory Distress Syndrome</condition>
  <condition>COVID-19 Pneumonia</condition>
  <arm_group>
    <arm_group_label>ICU patients with COVID-19</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NIRS monitoring will be performed for approximately 90 minutes at 2 mean blood pressure levels (MAP, ie 65-70 mmHg and 95-100 mmHg) within 12-48 hours and 60-84 hours after admission to the ICU for severe COVID-19 infection. Autoregulation will be assessed using Tissue Oxygenation Index values and mean arterial pressure values in a regression analysis and will be considered sufficient if the relative Pearson correlation coefficient is less than 0.3. Cerebral blood flow will be assessed by blood flow index determination after intravenous infusion of 5 mg indocyanine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NIRS (Near-Infrared Spectroscopy)</intervention_name>
    <description>NIRS assessment of cerebral autoregulation and cerebral blood flow</description>
    <arm_group_label>ICU patients with COVID-19</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Admission to ICU and endotracheal intubation/mechanical ventilation for severe&#xD;
             COVID-19 infection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patients with a terminal underlying disease who are unlikely to survive until&#xD;
             discharge from the hospital&#xD;
&#xD;
          -  Patients with acquired immunodeficiency and (&quot;pre-COVID&quot;) lymphocyte Cluster&#xD;
             Differentiation 4+ count &lt;50 / μL&#xD;
&#xD;
          -  Patients with COVID-19 who have been transferred from another hospital&#xD;
&#xD;
          -  Patients with a history of allergic reaction&#xD;
&#xD;
          -  Use of prone position to facilitate mechanical ventilation&#xD;
&#xD;
          -  Absence of signed informed consent from a first degree relative&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Spyros D Mentzelopoulos, MD, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>National and Kapodistrian University of Athens</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anastasia D Kotanidou, MD, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>National and Kapodistrian University of Athens</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Spyros D Mentzelopoulos, MD, Professor</last_name>
    <phone>+306975304909</phone>
    <email>sdmentzelopoulos@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anastasia Kotanidou, MD, Professor</last_name>
    <phone>+306977077105</phone>
    <email>akotanid@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Intensive Care Medicine Evaggelismos General Hospital</name>
      <address>
        <city>Athens</city>
        <state>Attica</state>
        <zip>10675</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evaggelismos G Hospital, MD, PhD</last_name>
      <phone>+306975304909</phone>
      <email>sdmentzelopoulos@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Anastasia D Kotanidou, MD, PhD</last_name>
      <phone>+306977077105</phone>
      <email>akotanid@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Ehler J, Barrett LK, Taylor V, Groves M, Scaravilli F, Wittstock M, Kolbaske S, Grossmann A, Henschel J, Gloger M, Sharshar T, Chretien F, Gray F, Nöldge-Schomburg G, Singer M, Sauer M, Petzold A. Translational evidence for two distinct patterns of neuroaxonal injury in sepsis: a longitudinal, prospective translational study. Crit Care. 2017 Oct 23;21(1):262. doi: 10.1186/s13054-017-1850-7.</citation>
    <PMID>29058589</PMID>
  </reference>
  <reference>
    <citation>Taccone FS, Castanares-Zapatero D, Peres-Bota D, Vincent JL, Berre' J, Melot C. Cerebral autoregulation is influenced by carbon dioxide levels in patients with septic shock. Neurocrit Care. 2010 Feb;12(1):35-42. doi: 10.1007/s12028-009-9289-6.</citation>
    <PMID>19806473</PMID>
  </reference>
  <reference>
    <citation>Schramm P, Klein KU, Falkenberg L, Berres M, Closhen D, Werhahn KJ, David M, Werner C, Engelhard K. Impaired cerebrovascular autoregulation in patients with severe sepsis and sepsis-associated delirium. Crit Care. 2012 Oct 4;16(5):R181. doi: 10.1186/cc11665.</citation>
    <PMID>23036135</PMID>
  </reference>
  <reference>
    <citation>Bindra J, Pham P, Chuan A, Jaeger M, Aneman A. Is impaired cerebrovascular autoregulation associated with outcome in patients admitted to the ICU with early septic shock? Crit Care Resusc. 2016 Jun;18(2):95-101.</citation>
    <PMID>27242107</PMID>
  </reference>
  <reference>
    <citation>Donnelly J, Budohoski KP, Smielewski P, Czosnyka M. Regulation of the cerebral circulation: bedside assessment and clinical implications. Crit Care. 2016 May 5;20(1):129. doi: 10.1186/s13054-016-1293-6. Review.</citation>
    <PMID>27145751</PMID>
  </reference>
  <reference>
    <citation>Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585. Erratum in: JAMA. 2021 Mar 16;325(11):1113.</citation>
    <PMID>32031570</PMID>
  </reference>
  <reference>
    <citation>Kaneko N, Satta S, Komuro Y, Muthukrishnan SD, Kakarla V, Guo L, An J, Elahi F, Kornblum HI, Liebeskind DS, Hsiai T, Hinman JD. Flow-Mediated Susceptibility and Molecular Response of Cerebral Endothelia to SARS-CoV-2 Infection. Stroke. 2021 Jan;52(1):260-270. doi: 10.1161/STROKEAHA.120.032764. Epub 2020 Nov 9.</citation>
    <PMID>33161843</PMID>
  </reference>
  <reference>
    <citation>Cagnazzo F, Piotin M, Escalard S, Maier B, Ribo M, Requena M, Pop R, Hasiu A, Gasparotti R, Mardighian D, Piano M, Cervo A, Eker OF, Durous V, Sourour NA, Elhorany M, Zini A, Simonetti L, Marcheselli S, Paolo NN, Houdart E, Guédon A, Ligot N, Mine B, Consoli A, Lapergue B, Cordona Portela P, Urra X, Rodriguez A, Bolognini F, Lebedinsky PA, Pasco-Papon A, Godard S, Marnat G, Sibon I, Limbucci N, Nencini P, Nappini S, Saia V, Caldiera V, Romano D, Frauenfelder G, Gallesio I, Gola G, Menozzi R, Genovese A, Terrana A, Giorgianni A, Cappellari M, Augelli R, Invernizzi P, Pavia M, Lafe E, Cavallini A, Giossi A, Besana M, Valvassori L, Macera A, Castellan L, Salsano G, Di Caterino F, Biondi A, Arquizan C, Lebreuche J, Galvano G, Cannella A, Cosottini M, Lazzarotti G, Guizzardi G, Stecco A, Tassi R, Bracco S, Bianchini E, Micieli C, Pascarella R, Napoli M, Causin F, Desal H, Cotton F, Costalat V; ET-COVID-19 Study Group*. European Multicenter Study of ET-COVID-19. Stroke. 2021 Jan;52(1):31-39. doi: 10.1161/STROKEAHA.120.031514. Epub 2020 Nov 23.</citation>
    <PMID>33222617</PMID>
  </reference>
  <reference>
    <citation>Alharthy A, Faqihi F, Papanikolaou J, Balhamar A, Blaivas M, Memish ZA, Karakitsos D. Thrombolysis in severe COVID-19 pneumonia with massive pulmonary embolism. Am J Emerg Med. 2021 Mar;41:261.e1-261.e3. doi: 10.1016/j.ajem.2020.07.068. Epub 2020 Jul 30.</citation>
    <PMID>32763101</PMID>
  </reference>
  <reference>
    <citation>Zangrillo A, Landoni G, Beretta L, Morselli F, Serpa Neto A, Bellomo R; COVID-BioB Study Group. Angiotensin II infusion in COVID-19-associated vasodilatory shock: a case series. Crit Care. 2020 May 15;24(1):227. doi: 10.1186/s13054-020-02928-0.</citation>
    <PMID>32414393</PMID>
  </reference>
  <reference>
    <citation>Dupont A, Rauch A, Staessens S, Moussa M, Rosa M, Corseaux D, Jeanpierre E, Goutay J, Caplan M, Varlet P, Lefevre G, Lassalle F, Bauters A, Faure K, Lambert M, Duhamel A, Labreuche J, Garrigue D, De Meyer SF, Staels B, Vincent F, Rousse N, Kipnis E, Lenting P, Poissy J, Susen S; Lille Covid Research Network (LICORNE). Vascular Endothelial Damage in the Pathogenesis of Organ Injury in Severe COVID-19. Arterioscler Thromb Vasc Biol. 2021 May 5;41(5):1760-1773. doi: 10.1161/ATVBAHA.120.315595. Epub 2021 Feb 25.</citation>
    <PMID>33626910</PMID>
  </reference>
  <reference>
    <citation>Ince C. The microcirculation is the motor of sepsis. Crit Care. 2005;9 Suppl 4:S13-9. Epub 2005 Aug 25. Review.</citation>
    <PMID>16168069</PMID>
  </reference>
  <reference>
    <citation>Donati A, Domizi R, Damiani E, Adrario E, Pelaia P, Ince C. From macrohemodynamic to the microcirculation. Crit Care Res Pract. 2013;2013:892710. doi: 10.1155/2013/892710. Epub 2013 Feb 27.</citation>
    <PMID>23509621</PMID>
  </reference>
  <reference>
    <citation>Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, Criner GJ, Kaplan-Lewis E, Baden R, Pandit L, Cameron ML, Garcia-Diaz J, Chávez V, Mekebeb-Reuter M, Lima de Menezes F, Shah R, González-Lara MF, Assman B, Freedman J, Mohan SV. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med. 2021 Jan 7;384(1):20-30. doi: 10.1056/NEJMoa2030340. Epub 2020 Dec 17.</citation>
    <PMID>33332779</PMID>
  </reference>
  <reference>
    <citation>Jamil S, Mark N, Carlos G, Cruz CSD, Gross JE, Pasnick S. Diagnosis and Management of COVID-19 Disease. Am J Respir Crit Care Med. 2020 May 15;201(10):P19-P20. doi: 10.1164/rccm.2020C1.</citation>
    <PMID>32223716</PMID>
  </reference>
  <reference>
    <citation>Goodson CM, Rosenblatt K, Rivera-Lara L, Nyquist P, Hogue CW. Cerebral Blood Flow Autoregulation in Sepsis for the Intensivist: Why Its Monitoring May Be the Future of Individualized Care. J Intensive Care Med. 2018 Feb;33(2):63-73. doi: 10.1177/0885066616673973. Epub 2016 Oct 25. Review.</citation>
    <PMID>27798314</PMID>
  </reference>
  <reference>
    <citation>Nakagawa I, Park HS, Yokoyama S, Yamada S, Motoyama Y, Park YS, Wada T, Kichikawa K, Nakase H. Indocyanine green kinetics with near-infrared spectroscopy predicts cerebral hyperperfusion syndrome after carotid artery stenting. PLoS One. 2017 Jul 12;12(7):e0180684. doi: 10.1371/journal.pone.0180684. eCollection 2017.</citation>
    <PMID>28704454</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 15, 2021</study_first_submitted>
  <study_first_submitted_qc>June 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Athens</investigator_affiliation>
    <investigator_full_name>Spyros D. Mentzelopoulos</investigator_full_name>
    <investigator_title>Professor of Intensive Care Medicine, National and Kapodistrian University of Athens Medical School</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Cerebrovascular circulation</keyword>
  <keyword>Spectroscopy, Near-Infrared</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

